ENDRA Life Sciences Inc. (NDRA) |
| 4.95 0.175 (3.66%) 10-15 14:03 |
| Open: | 4.97 |
| High: | 5.14 |
| Low: | 4.95 |
| Volume: | 9,021 |
| Market Cap: | 7(M) |
| PE Ratio: | -0.74 |
| Exchange: | NASDAQ Capital Market |
| Industry: | Medical - Diagnostics & Research |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 6.67 |
| Resistance 1: | 5.93 |
| Pivot price: | 5.69 |
| Support 1: | 4.73 |
| Support 2: | 3.94 |
| 52w High: | 7.55 |
| 52w Low: | 2.96 |
ENDRA Life Sciences Inc. specializes in advancing the capabilities of clinical diagnostic ultrasound. The company's primary development is thermo-acoustic enhanced ultrasound technology, which operates by emitting sound waves that echo off internal body components such as tissues, organs, and blood. This innovation is utilized in managing nonalcoholic fatty liver disease, meticulously monitoring temperature during thermoablative surgical procedures, detailed vascular imaging, and assessing tissue perfusion. Furthermore, ENDRA offers other diagnostic imaging modalities, including computed tomography (CT), magnetic resonance imaging (MRI), and conventional ultrasound. These instruments empower physicians to visualize internal anatomy, aiding in treatment guidance and the identification of various medical conditions like bone fractures, cancerous growths, indicators of heart disease, or internal bleeding. The company also maintains a research collaboration agreement with General Electric Company. Established in 2007, ENDRA Life Sciences Inc. is headquartered in Ann Arbor, Michigan.
| EPS | -5.820 |
| Book Value | 4.210 |
| PEG Ratio | 0.00 |
| Gross Profit | 0.000 |
| Profit Margin (%) | 0.00 |
| Operating Margin (%) | 0.00 |
| Return on Assets (ttm) | -77.3 |
| Return on Equity (ttm) | -152.0 |
Thu, 08 Oct 2026
A 10% owner holds warrants with a $0.0001 exercise price in ENDRA Life Sciences (NDRA). - Stock Titan
Thu, 08 Oct 2026
187,169 warrant shares are part of ASP Isotopes' stake in ENDRA Life Sciences (NDRA). - Stock Titan
Fri, 02 Oct 2026
ASP Isotopes announces ENDRA Life Sciences S-4 filing for planned merger - Investing.com
Fri, 02 Oct 2026
ENDRA Life Sciences Amends Merger Agreement and Warrants - The Globe and Mail
Thu, 01 Oct 2026
A three-class board is off the table as ENDRA Life Sciences (NDRA) revises proposed merger terms. - Stock Titan
Thu, 01 Oct 2026
Lhe Lng Holdings Llc Net Worth (2026) - GuruFocus
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |